1. Dexycu is applied as a single, post-surgery injection.
2. The drug uses Icon Bioscience’s extended-release drug-dispensing technology to inject dexamethasone into the eye’s posterior chamber.
3. Typical treatment for inflammation after cataract surgery involves self-administering medicated eye drops several times daily for several weeks.
4. More than 4 million cataract surgeries are performed annually in the U.S., on a largely elderly population.
5. “As Icon steps across the threshold from R&D to an approved product, we look forward to announcing our plans to bring Dexycu into the marketplace,” said Icon Bioscience President and CEO David Tierney, MD.
More articles on supply chain:
Medical software company raises $3.2M for value-based IT system – 5 highlights
Terumo Corp. to make major investment in medical implants factory — 5 notes
McKesson reports $53.6B in Q3 revenue — 7 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.